Synthesis and biological evaluation of novel phenothiazine derivatives as non-peptide arginine vasopressin V2 receptor antagonists

被引:0
|
作者
Shuang Zhi [1 ]
Shuai Mu [1 ,2 ]
Ying Liu [2 ]
Min Gong [2 ]
Ping-Bao Wang [2 ]
Deng-Ke Liu [2 ]
机构
[1] School of Chemical Engineering and Technology,Tianjin University
[2] Tianjin Institute of Pharmaceutical Research
关键词
Arginine vasopressin V2 receptor; antagonist; Phenothiazine derivatives; Synthesis; Biological activities;
D O I
暂无
中图分类号
O626 [杂环化合物];
学科分类号
摘要
A series of novel phenothiazine derivatives was synthesized and tested for arginine vasopressin receptor antagonist activity.They were synthesized as novel arginine vasopressin receptor antagonists from phenothiazine as a scaffold via successive acylation,reduction and acylation reactions.Their structures were characterized by ~1H NMR,C NMR and HRMS,and biological activity was evaluated by in vitro and in vivo studies.The in vitro binding assay indicated that several compounds are potent selective V2 receptor antagonists.Compounds with promising binding affinity to V2 receptors were selected to conduct the in vivo diuretic studies on Sprague-Dawley rats.Among them.In,1r,1t and 1v exhibited excellent diuretic activity,especially 1 rand 1 v.Therefore,1r and 1v are potent novel AVPV2 receptor antagonist candidates.
引用
收藏
页码:627 / 630
页数:4
相关论文
共 50 条
  • [31] Chapter 16. Vasopressin receptor modulators: From non-peptide antagonists to agonists
    Trybulski, EJ
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 36, 2001, 36 : 159 - 168
  • [32] Non-Peptide Arginine-Vasopressin Antagonists (Vaptans) for the Treatment of Hyponatremia in Neurocritical Care: A New Alternative?
    Fields, Jeremy D.
    Bhardwaj, Anish
    NEUROCRITICAL CARE, 2009, 11 (01) : 1 - 4
  • [33] Non-Peptide Arginine-Vasopressin Antagonists (Vaptans) for the Treatment of Hyponatremia in Neurocritical Care: A New Alternative?
    Jeremy D. Fields
    Anish Bhardwaj
    Neurocritical Care, 2009, 11 : 1 - 4
  • [34] Identification of residues responsible for the selective binding of peptide antagonists and agonists in the V2 vasopressin receptor.
    Cotte, N
    Balestre, MN
    Phalipou, S
    Hibert, M
    Manning, M
    Barberis, C
    Mouillac, B
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 358 (01) : R709 - R709
  • [35] A novel splicing mutation in the V2 vasopressin receptor
    Kamperis, K
    Siggaard, C
    Herlin, T
    Nathan, E
    Hertz, JM
    Rittig, S
    PEDIATRIC NEPHROLOGY, 2000, 15 (1-2) : 43 - 49
  • [36] A novel splicing mutation in the V2 vasopressin receptor
    K. Kamperis
    C. Siggaard
    T. Herlin
    E. Nathan
    J. M. Hertz
    S. Rittig
    Pediatric Nephrology, 2000, 15 : 43 - 49
  • [37] Synthesis and characterization of orally active nonpeptide arginine vasopressin V2 receptor antagonist.
    Ohkawa, T
    Setoi, H
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 213 : 104 - MEDI
  • [38] Preparation of highly potent and selective non-peptide antagonists of the arginine vasopressin V1A receptor by introduction of a 2-ethyl-1H-1-imidazolyl group
    Shimada, Y
    Akane, H
    Taniguchi, N
    Matsuhisa, A
    Kawano, N
    Kikuchi, K
    Yatsu, T
    Tahara, A
    Tomura, Y
    Kusayama, T
    Wada, K
    Tsukada, J
    Tsunoda, T
    Tanaka, A
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2005, 53 (07) : 764 - 769
  • [40] Discovery of novel non-peptide CCR1 receptor antagonists
    Ng, HP
    May, K
    Bauman, JG
    Ghannam, A
    Islam, I
    Liang, M
    Horuk, R
    Hesselgesser, J
    Snider, RM
    Perez, HD
    Morrissey, MM
    JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (22) : 4680 - 4694